Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Meredith McKean, Matthew H. Carabasi, Mark N. Stein, Michael Thomas Schweizer, Jason J. Luke, Vivek Narayan, Rahul Atul Parikh, Russell Kent Pachynski, Jingsong Zhang, Vijay Gopal Reddy Peddareddigari, James Winnberg, Amy Roberts, Jamie Rosen, Pam Hufner, Whitney Gladney, Thomas J. Fountaine, Karen Chagin
Institutions: Sarah Cannon, Tennessee Oncology, Thomas Jefferson University, Columbia University Irving Medical Center, University of Washington, Fred Hutch Cancer Center, UPMC Hillman Cancer Center, University of Pennsylvania, University of Kansas Medical Center, Washington University in St. Louis, Moffitt Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4213049486